Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/09/24
Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/09/24
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.GlobeNewsWire • 11/08/24
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated ApprovalGlobeNewsWire • 11/04/24
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)GlobeNewsWire • 11/01/24
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney WeekGlobeNewsWire • 10/25/24
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney WeekGlobeNewsWire • 10/11/24
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory OfficerGlobeNewsWire • 09/19/24
Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 ProgressSeeking Alpha • 06/14/24
Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 CongressGlobeNewsWire • 06/14/24
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 CongressGlobeNewsWire • 05/14/24
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor ConferenceGlobeNewsWire • 05/13/24
Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/09/24
Top 3 Health Care Stocks You'll Regret Missing This Month - Humana (NYSE:HUM), Disc Medicine (NASDAQ:IRON)Benzinga • 04/02/24
Disc Medicine Plummets 59% After Placebo Effect Confounds Sunlight Sensitivity StudyInvestors Business Daily • 04/01/24
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)GlobeNewsWire • 04/01/24
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/21/24
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024GlobeNewsWire • 03/06/24
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial OfficerGlobeNewsWire • 02/26/24
Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney DiseaseGlobeNewsWire • 02/20/24